1) Strong Financial Performance - IQVIA reported Q2 2026 revenue of $4.368 billion, up 8.7% YoY, exceeding guidance. - Adjusted EBITDA grew 9.2% YoY to $994 million. - Adjusted diluted EPS was $3.15, reflecting a 12.1% increase YoY. - Organic growth accelerated to 6%, three times the previous year’s rate.

2) Segment Highlights - R&D Solutions revenue reached $2.575 billion, up 8.8% YoY, with net new bookings of $3.15 billion, a 19% increase YoY. - Commercial Solutions revenue was $1.793 billion, up 8.6% YoY, driven by strong demand for analytics and consulting services. - The book-to-bill ratio for R&D Solutions was 1.22, indicating strong demand and operational performance.

3) Market Dynamics and Demand Trends - The clinical environment is seeing strong RFP flow growth, with double-digit increases YoY and sequentially. - Emerging biopharma (EBP) companies now represent 70% of all clinical trial starts, highlighting a shift in industry dynamics. - Increased drug launches (up 45% YoY) are driving demand for commercial solutions.

4) Operational Improvements and AI Integration - Adjusted EBITDA margins improved due to operational productivity programs, with AI contributing significantly to efficiency. - IQVIA is expanding its AI capabilities, with 294 agents deployed across 90 use cases to enhance clinical trial outcomes. - The company is focusing on integrating AI into its offerings to improve study design and patient recruitment.

5) Guidance and Future Outlook - Full-year 2026 revenue guidance raised to $17.275 billion - $17.475 billion, reflecting 5.9% to 7.1% growth. - Adjusted EBITDA guidance increased to $4 billion - $4.05 billion, with adjusted diluted EPS expected between $12.80 and $13.00. - The call did not provide specific details on the impact of FX and pass-throughs on future margins.

Bottom line: IQVIA's robust Q2 performance, driven by strong operational execution and growing demand in both clinical and commercial segments, positions the company favorably for continued growth. The raised guidance reflects confidence in sustaining this momentum, making it an attractive prospect for shareholders.